ABVX:EPA
Abivax SA
€83.50
arrow_downward
-0.77%(-0.65) 1D
Oct 2, 5:35:23 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
€83.65
High
€85.20
Low
€82.80
Mkt. cap
7.20B
Avg. vol.
154.69K
Volume
120.39K
52-wk high
€139.00
52-wk low
€60.45
EPS
-€5.20
Shares outstanding
87.53M
No. of employees
98
Open
€83.65
High
€85.20
Low
€82.80
Mkt. cap
7.20B
Avg. vol.
154.69K
Volume
120.39K
52-wk high
€139.00
52-wk low
€60.45
EPS
-€5.20
Shares outstanding
87.53M
No. of employees
98
News stories
From web sources and news partners
Foreign Policy Journal
·
1 hour ago
Supreme Court Cases Involving Apple (NASDAQ: AAPL), Exxon (NYSE: XOM), And Intel (NASDAQ: INTC) Could Reshape Investor Portfolios
Simply Wall Street
·
23 minutes ago
October 2026 Founder Led Stocks To Watch
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
FoundedDec 4, 2013
Headquarters-
SectorBiotechnology
Websiteabivax.com